1-4 of 4
dihydrofolate reductase inhibitors
Close
Sort by
Journal Articles

Pralatrexate: Phase 1/2 Study in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Yoshinobu Maeda, MD PhD, Kensei Tobinai, MD, PhD, Hirokazu Nagai, MD PhD, Takahiko Nakane, MD, PhD, Tatsu Shimoyama, MD, Tomonori Nakazato, Rika Sakai, Takayuki Ishikawa, MD, PhD, Koji Izutsu, MD PhD, Ryuzo Ueda, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4157.
https://doi.org/10.1182/blood.V128.22.4157.4157
Published: 2016
Journal Articles

High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia

Amit Sharma, PhD, Nidhi Jyotsana, Courteney K. Lai, BSc, Anuhar Chaturvedi, PhD, Kerstin Görlich, Cecilia Murphy, Jan E. Blanchard, Arnold Ganser, Eric Brown, John A. Hassell, R. Keith Humphries, MD PhD, Michael A Morgan, PhD, Michael Heuser, MD
Journal: Blood
Blood (2014) 124 (21): 2304.
https://doi.org/10.1182/blood.V124.21.2304.2304
Published: 2014
Journal Articles

Identification of AML1-ETO modulators by chemical genomics

Steven M. Corsello, Giovanni Roti, Kenneth N. Ross, Kwan T. Chow, Ilene Galinsky, Daniel J. DeAngelo, Richard M. Stone, Andrew L. Kung, Todd R. Golub, Kimberly Stegmaier
Journal: Blood
Blood (2009) 113 (24): 6193–6205.
https://doi.org/10.1182/blood-2008-07-166090
Published: 2009
Includes: Supplemental data
Journal Articles

Modulating AML1-ETO with Signature-Based Small Molecule Library Screening.

Kimberly Stegmaier, MD, Steven M. Corsello, Kenneth N. Ross, Ph.D., Todd R. Golub, M.D.
Journal: Blood
Blood (2006) 108 (11): 729.
https://doi.org/10.1182/blood.V108.11.729.729
Published: 2006